Intersect ENT (NASDAQ: XENT) announced positive results from three clinical studies evaluating treatment of patients with sinus disease in the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE